BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
134.05
-4.35 (-3.14%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Company Description

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.

Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.

The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic.

It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BeiGene, Ltd.
BeiGene logo
Country United States
Founded 2010
IPO Date Feb 3, 2016
Industry Biotechnology
Sector Healthcare
Employees 10,600
CEO John V. Oyler

Contact Details

Address:
C/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
Grand Cayman, E9 KY1-1108
Cayman Islands
Phone 13459494123
Website beigene.com

Stock Details

Ticker Symbol BGNE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001651308
CUSIP Number 07725L102
ISIN Number US07725L1026
Employer ID 98-1209416
SIC Code 2834

Key Executives

Name Position
John V. Oyler Co-Founder, Executive Chairman and Chief Executive Officer
Dr. Xiaobin Wu Ph.D. President and Chief Operating Officer
Dr. Xiaodong Wang Ph.D. Co- Chairman of Scientific Advisory Board and Non-Executive Director Co-Founder
Julia Wang Chief Financial Officer and Principal Financial Officer
Wang Lai Ph.D. Global Head of Research & Development
Titus B. Ball Vice President and Chief Accounting Officer
Liza Heapes Head of Investor Relations
Chan Lee General Counsel and Senior Vice President
Yang Ji Chief Compliance Officer
Dr. Yan Qi Senior Vice President and Head of Public Affairs - Greater China

Latest SEC Filings

Date Type Title
Apr 15, 2024 PRE 14A Other preliminary proxy statements
Apr 9, 2024 144 Filing
Mar 26, 2024 144 Filing
Mar 20, 2024 8-K Current Report
Mar 15, 2024 8-K Current Report
Mar 12, 2024 144 Filing
Mar 8, 2024 8-K Current Report
Feb 29, 2024 144 Filing
Feb 26, 2024 10-K Annual Report
Feb 26, 2024 8-K Current Report